PMID- 36470722
OWN - NLM
STAT- MEDLINE
DCOM- 20230728
LR  - 20231011
IS  - 1878-3562 (Electronic)
IS  - 1590-8658 (Linking)
VI  - 55
IP  - 8
DP  - 2023 Aug
TI  - Effectiveness and safety of 1-L PEG-ASC versus other bowel preparations for 
      colonoscopy: A meta-analysis of nine randomized clinical trials.
PG  - 1010-1018
LID - S1590-8658(22)00788-5 [pii]
LID - 10.1016/j.dld.2022.11.010 [doi]
AB  - BACKGROUND AND AIMS: A 1-L polyethylene glycol plus ascorbate (PEG-ASC) 
      preparation has been recently developed to improve patients' experience in 
      colonoscopy. This meta-analysis aimed to evaluate the effectiveness and safety of 
      1-L PEG-ASC compared with those of other bowel preparations for colonoscopy. 
      METHODS: MEDLINE, Embase, Scopus, and the Cochrane Library were systematically 
      searched for randomized controlled trials comparing 1-L PEG-ASC with other bowel 
      preparations published through July 2022. A random-effects model was applied for 
      pooling the results; heterogeneity was expressed as I(2). RESULTS: Nine studies 
      met the inclusion criteria and were included. The analysis showed significantly 
      higher cleansing success (CS) (OR = 1.50; 95% CI = 1.25-1.81; p < 0.01, 
      I(2) = 0%) and right-colon high-quality cleansing (HQC) (OR = 1.67; 95% 
      CI = 1.21-2.31; p < 0.01, I(2) = 43%) with 1-L PEG-ASC compared to the other 
      preparations. The pooled estimate of the adenoma detection rate (ADR) did not 
      significantly differ between the two groups either in the overall (OR = 1.02; 95% 
      CI = 0.87-1.20; p = 0.79, I(2) = 0%) or split-dosing regimen subgroup analysis 
      (OR = 0.99; 95% CI = 0.84-1.18; p = 0.94, I(2) = 0%). A significantly higher 
      pooled estimate of the number of patients with adverse events (AEs) (OR = 1.51; 
      95% CI = 1.23-1.84; p<0.01, I(2) = 0%) and incidence of AEs (IRR=1.33; 95% 
      CI = 1.11-1.58; p<0.01, I(2) = 71%) was observed with 1-L PEG-ASC than with the 
      other preparations. No serious AEs or deaths occurred. CONCLUSIONS: Compared to 
      other preparations, 1-L PEG-ASC yielded higher overall CS, higher right-colon HQC 
      rates, and similar ADR. The number of patients with AEs and incidence of the 
      total AEs were significantly higher with 1-L PEG-ASC in the absence of serious 
      AEs.
CI  - Copyright (c) 2022 Editrice Gastroenterologica Italiana S.r.l. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Maida, M
AU  - Maida M
AD  - Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta, 
      Italy. Electronic address: marcello.maida@hotmail.it.
FAU - Ventimiglia, M
AU  - Ventimiglia M
AD  - Directorate General of Medical Device and Pharmaceutical Service, Italian 
      Ministry of Health, Rome, Italy.
FAU - Facciorusso, A
AU  - Facciorusso A
AD  - Gastroenterology Unit, Department of Medical Sciences, University of Foggia, 
      Foggia, Italy.
FAU - Vitello, A
AU  - Vitello A
AD  - Gastroenterology and Endoscopy Unit, S. Elia-Raimondi Hospital, Caltanissetta, 
      Italy.
FAU - Sinagra, E
AU  - Sinagra E
AD  - Gastroenterology and Endoscopy Unit, Fondazione Instituto San Raffaele Giglio, 
      Cefalu, Italy.
FAU - Marasco, G
AU  - Marasco G
AD  - IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy; Department of 
      Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20221202
PL  - Netherlands
TA  - Dig Liver Dis
JT  - Digestive and liver disease : official journal of the Italian Society of 
      Gastroenterology and the Italian Association for the Study of the Liver
JID - 100958385
RN  - 0 (Cathartics)
RN  - 0 (Laxatives)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
EIN - Dig Liver Dis. 2023 Dec;55(12):1782. PMID: 37821257
MH  - Humans
MH  - *Cathartics/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Laxatives
MH  - Polyethylene Glycols/adverse effects
MH  - Colonoscopy/methods
MH  - Ascorbic Acid/adverse effects
MH  - *Adenoma/diagnosis
OTO - NOTNLM
OT  - ADR
OT  - Bowel preparation
OT  - Colonoscopy
OT  - PEG-ASC
OT  - Polyethylene glycol
OT  - Safety
COIS- Declaration of Competing Interest Marcello Maida served as advisory board member 
      and received lecture grants from Norgine. Giovanni Marasco received consultation 
      fees from AlfaSigma. Other authors have no proprietary, financial, professional 
      or other personal interest of any nature or kind in any product, service and/or 
      company that could be construed as influencing the position presented in, or the 
      review of this manuscript.
EDAT- 2022/12/06 06:00
MHDA- 2023/07/28 06:42
CRDT- 2022/12/05 22:05
PHST- 2022/08/31 00:00 [received]
PHST- 2022/10/30 00:00 [revised]
PHST- 2022/11/08 00:00 [accepted]
PHST- 2023/07/28 06:42 [medline]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/05 22:05 [entrez]
AID - S1590-8658(22)00788-5 [pii]
AID - 10.1016/j.dld.2022.11.010 [doi]
PST - ppublish
SO  - Dig Liver Dis. 2023 Aug;55(8):1010-1018. doi: 10.1016/j.dld.2022.11.010. Epub 
      2022 Dec 2.